Cargando…

A multicenter, retrospective study of patients with pulmonary arterial hypertension transitioned from parenteral prostacyclin therapy to inhaled iloprost

Pulmonary arterial hypertension (PAH) is characterized by progressive increases in pulmonary vascular resistance, leading to right heart failure and death. Guidelines recommend customization of treatment, necessitating the development of effective strategies for transitioning patients among treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Channick, Richard N., Frantz, Robert P., Kawut, Steven M., Palevsky, Harold, Tumuluri, Ramagopal, Sulica, Roxana, Lauto, Paula O., Benton, Wade W., de Boisblanc, Bennett
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3757833/ https://www.ncbi.nlm.nih.gov/pubmed/24015339 http://dx.doi.org/10.4103/2045-8932.114768

Ejemplares similares

Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs
por: Schermuly, Ralph T, et al.
Publicado: (2007)

The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis
por: Colasanti, Tania, et al.
Publicado: (2022)

Rapid Transition from Inhaled Iloprost to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
por: Bourge, Robert C, et al.
Publicado: (2013)

A prostacyclin analogue, iloprost, protects from bleomycin-induced pulmonary fibrosis in mice
por: Zhu, Yuanjue, et al.
Publicado: (2010)

Inhaled iloprost for the control of pulmonary hypertension
por: Krug, Sabine, et al.
Publicado: (2009)

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
por: Aldweib, Nael, et al.
Publicado: (2021)

Inhaled iloprost for the treatment of patient with Fontan circulation
por: Kim, Yong Hyun, et al.
Publicado: (2014)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

The pulmonary and haematological toxicity of inhaled aerosolised prostacyclin
por: van Heerden, PV, et al.
Publicado: (1997)

Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers
por: Boucly, Athénaïs, et al.
Publicado: (2022)

Review of inhaled iloprost for the control of pulmonary artery hypertension in children
por: Tissot, Cecile, et al.
Publicado: (2009)

Inhaled prostacyclin therapy in the acute respiratory distress syndrome: a randomized controlled multicenter trial
por: Haeberle, Helene A., et al.
Publicado: (2023)

Outcome of painful bone marrow edema of the femoral head following treatment with parenteral iloprost
por: Meizer, Roland, et al.
Publicado: (2009)

Use of Inhaled Iloprost in an Infant With Bronchopulmonary Dysplasia and Pulmonary Artery Hypertension
por: Hwang, Seung-Kyung, et al.
Publicado: (2009)

Inhaled iloprost as third add-on therapy in idiopathic pulmonary arterial hypertension
por: Fernandes, Caio J.C.S., et al.
Publicado: (2021)

Inhaled iloprost is an effective alternative therapy for persistent pulmonary hypertension in newborns
por: Yıldırım, Şükran
Publicado: (2023)

Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis
por: Song, Ci, et al.
Publicado: (2022)

Acute hemodynamic effect of inhaled iloprost in pulmonary artery hypertension evaluated with echocardiography
por: Loureiro, Maria José, et al.
Publicado: (2007)

Inhaled Iloprost for Patients With Precapillary Pulmonary Hypertension and Right-Side Heart Failure
por: Martischnig, Amadea M., et al.
Publicado: (2011)

Effects of inhaled iloprost on acute respiratory distress syndrome in prone and supine positions
por: Senturk, E, et al.
Publicado: (2009)

Survival with sildenafil and inhaled iloprost in a cohort with pulmonary hypertension: an observational study
por: Gall, Henning, et al.
Publicado: (2016)

Hemodynamic and gas exchange effects of inhaled iloprost in patients with COPD and pulmonary hypertension
por: Wang, Lan, et al.
Publicado: (2017)

Switching inhaled iloprost formulations in patients with pulmonary arterial hypertension: the VENTASWITCH Trial
por: Richter, Manuel J., et al.
Publicado: (2018)

Inhaled iloprost can improve oxygenation and shunt fraction in severe COVID-19
por: Serbanescu-Kele Apor de Zalán, Christiaan M.C., et al.
Publicado: (2022)

Effects of inhaled iloprost on right ventriculovascular coupling and ventricular interdependence in acute pulmonary hypertension
por: Rex, S, et al.
Publicado: (2008)

Comparison of levosimendan, NO, and inhaled iloprost for pulmonary hypertension reversibility assessment in heart transplant candidates
por: Tavares‐Silva, Marta, et al.
Publicado: (2021)

Long-term effects of intravenous iloprost in patients with idiopathic pulmonary arterial hypertension deteriorating on non-parenteral therapy
por: Knudsen, Lars, et al.
Publicado: (2011)

Saudi experience in the management of pulmonary arterial hypertension; the outcome of PAH therapy with the exclusion of chronic parenteral prostacyclin
por: Idrees, Majdy, et al.
Publicado: (2015)

Prognosis of pulmonary arterial hypertension patients with pericardial effusion before and after initiation of parenteral prostacyclin therapy
por: Abu‐Rmaileh, Muhammad, et al.
Publicado: (2023)

Comparison of inhaled milrinone, nitric oxide and prostacyclin in acute respiratory distress syndrome
por: Albert, Martin, et al.
Publicado: (2017)

Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature
por: Magnani, Luca, et al.
Publicado: (2023)

Efficacy of Inhaled Iloprost in Cor Pulmonale and Severe Pulmonary Hypertension Associated with Tuberculous Destroyed Lung
por: Park, Yae Min, et al.
Publicado: (2014)

The optimization of iloprost inhalation under moderate flow of oxygen therapy in severe pulmonary arterial hypertension
por: Nakayama, Kazuhiko, et al.
Publicado: (2018)

Inhaled iloprost improves gas exchange in patients with COVID-19 and acute respiratory distress syndrome
por: Tsareva, Natalia A., et al.
Publicado: (2021)

Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment
por: Miller, York E., et al.
Publicado: (2023)

Inhaled Prostacyclins for Acute Respiratory Distress Syndrome: A Systematic Review and Meta-Analysis
por: Torbic, Heather, et al.
Publicado: (2023)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
por: Alqarni, Abdullah A., et al.
Publicado: (2023)

Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors
por: Schermuly, Ralph Theo, et al.
Publicado: (2005)

Hyperbaric Oxygen Therapy with Iloprost Improves Digit Salvage in Severe Frostbite Compared to Iloprost Alone
por: Magnan, Marie-Anne, et al.
Publicado: (2021)

Right ventricular function mirrors clinical improvement with use of prostacyclin analogues in pediatric pulmonary hypertension
por: Hopper, Rachel K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d8ukm717a39vmhmjd6jqfd1cil